Article
Glycan shielding and epitope reorganization drive sotrovimab resistance in SARS-CoV-2 Omicron variants.
Archives of biochemistry and biophysics - 1 Aug 2026
Kumar Ankit, Yadav Amar Jeet, Tripathi Timir, Padhi Aditya K
Abstract excerpt
The rapid antigenic evolution of the SARS-CoV-2 spike protein has progressively eroded the efficacy of therapeutic monoclonal antibodies, including sotrovimab. Omicron BA.1 and BA.2 variants exhibit markedly reduced neutralization potency; however, the molecular and energetic mechanisms underlying this resistance, particularly the contribution of glycan-mediated epitope reorganization, remain insufficiently...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
